Disease Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

ID DOID:11934
Name head and neck cancer
Definition An organ system cancer that arises in the head or neck region. This region includes the nasal cavity, sinuses, lips, mouth, salivary glands, throat, or larynx.
Source DiseaseOntology.org
Alt Ids
Path disease disease of cellular proliferation cancer organ system cancer head and neck cancer

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
TP53 R175H ReACp53 head and neck cancer sensitive detail...
ALK wild-type Cisplatin + Dalantercept head and neck cancer predicted - sensitive detail...
ATM loss Ceralasertib + Olaparib head and neck cancer predicted - sensitive detail...
BRAF G469A Ulixertinib head and neck cancer sensitive detail...
PIK3CA mutant Alpelisib head and neck cancer sensitive detail...
ATM del AZD7648 + Olaparib head and neck cancer sensitive detail...
ATM del AZD7648 head and neck cancer sensitive detail...
ATM del Olaparib head and neck cancer sensitive detail...
CD274 positive Pembrolizumab head and neck cancer sensitive detail...
PIK3CA mutant WX390 head and neck cancer predicted - sensitive detail...
PTEN inact mut RMC-5552 head and neck cancer predicted - sensitive detail...
CD274 positive Ipilimumab + Nivolumab head and neck cancer sensitive detail...
Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT00903461 Phase Ib/II EGFR Antisense DNA Safety and Efficacy of Radiation/Cetuximab Plus EGFR Antisense DNA for Head and Neck Squamous Cell Carcinoma Terminated USA 0
NCT00970502 Phase Ib/II Celecoxib + Erlotinib Erlotinib, Celecoxib and Reirradiation for Recurrent Head and Neck Cancer Completed USA 0
NCT00978250 Phase II 5-Fluoro-2-deoxycytidine + Tetrahydrouridine A Multi-Histology Phase II Study of 5-Fluoro-2-Deoxycytidine With Tetrahydrouridine (FdCyd + THU) Completed USA 0
NCT01218048 Phase II Cisplatin Carboplatin Cetuximab ERBITUX; Followed by Adjuvant Treatment With Chemoradiation and ERBITUX; for Locally Advanced Head and Neck Squamous Cell Carcinoma Completed USA 0
NCT01351103 Phase I LGK974 LGK974 + Spartalizumab A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands Active, not recruiting USA | ITA | FRA | ESP | DEU | CAN 1
NCT01391143 Phase I MGA271 Safety Study of MGA271 in Refractory Cancer Completed USA 0
NCT01588431 Phase II Cetuximab + Cisplatin + Docetaxel Bevacizumab Bevacizumab/Ph 2 for Locally Advanced Head and Neck Cancer Completed USA 0
NCT01831089 Phase I Bevacizumab + Lurbinectedin + Paclitaxel Lurbinectedin + Paclitaxel Phase I Study of Lurbinectedin (PM01183) in Combination With Paclitaxel, With or Without Bevacizumab, in Selected Advanced Solid Tumors Completed USA | ESP 1
NCT01835626 Phase II Vismodegib Phase II Study of Radiation Therapy and Vismodegib for Advanced Head/Neck Basal Cell Carcinoma Completed USA 0
NCT01874860 Phase I Doxycycline Skin Rash Study Before Chemotherapy in Colorectal & Head and Neck Cancer Patients Completed USA 0
NCT01968109 Phase I Nivolumab + Relatlimab Relatlimab Safety Study of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid Tumors Active, not recruiting USA | ITA | GBR | FRA | ESP | DEU | CAN | AUT | AUS 6
NCT01976741 Phase I Rogaratinib Phase I Dose Escalation Pan-FGFR (Fibroblast Growth Factor Receptor) Inhibitor Completed USA | FRA | ESP | DEU 3
NCT02004106 Phase I Cergutuzumab amunaleukin A Study of RO6895882 in Patients With Advanced and/or Metastatic Solid Tumors Completed USA | GBR | FRA | ESP 4
NCT02014909 Phase I CDX-3379 CDX-3379 + Vemurafenib CDX-3379 + Trastuzumab CDX-3379 + Cetuximab CDX-3379 + Erlotinib A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of KTN3379 in Adult Subjects With Advanced Tumors Completed USA 0
NCT02051751 Phase I Alpelisib + Paclitaxel A Study to Evaluate the Potential Benefit of the Addition of BYL719 to Paclitaxel in the Treatment of Breast Cancer and Head-and-neck Cancer Completed USA | ITA | FRA | ESP 0
NCT02107235 Phase I Cisplatin Rigosertib Sodium Platinum-based Chemoradiotherapy and Rigosertib in Head and Neck Cancer Completed USA 0
NCT02113878 Phase I Buparlisib + Cisplatin Phase Ib Study of BKM120 With Cisplatin and XRT in High Risk Locally Advanced Squamous Cell Cancer of Head and Neck Completed USA 0
NCT02318771 Phase I Pembrolizumab Radiation Therapy and MK-3475 for Patients With Recurrent/Metastatic Head and Neck Cancer, Renal Cell Cancer, Urothelial Cancer, Melanoma, and Non-Small Cell Lung Cancer Completed USA 0
NCT02454972 Phase II Lurbinectedin Clinical Trial of Lurbinectedin (PM01183) in Selected Advanced Solid Tumors Completed USA | ITA | GBR | FRA | ESP | DEU | BEL 2
NCT02471846 Phase I Navoximod Atezolizumab A Study of GDC-0919 and MPDL3280A Combination Treatment in Participants With Locally Advanced or Metastatic Solid Tumors Completed USA | FRA | ESP 1
NCT02488759 Phase Ib/II Nivolumab A Study to Investigate the Safety and Efficacy of Nivolumab in Virus-associated Tumors (CheckMate358) Completed USA | GBR | FRA | ESP | DEU | BEL 5
NCT02538627 Phase I Seribantumab MM-151 Phase 1 Combination Study of MM-151 and MM-121 Terminated USA 0
NCT02543645 Phase Ib/II Atezolizumab + Varlilumab A Study of Varlilumab and Atezolizumab in Patients With Advanced Cancer Terminated USA 0
NCT02646319 Phase I Nab-rapamycin Nanoparticle Albumin-Bound Rapamycin in Treating Patients With Advanced Cancer With mTOR Mutations Completed USA 0
NCT02671955 Phase I Onvatilimab A Study of Safety, Pharmacokinetics, Pharmacodynamics of JNJ-61610588 in Participants With Advanced Cancer Terminated USA 0
NCT02710396 Phase II Carboplatin + Pembrolizumab + Pemetrexed Disodium Pembrolizumab Carboplatin + Nab-paclitaxel + Pembrolizumab Genetic Predictors of Benefit to Pembrolizumab Terminated USA 0
NCT02841748 Phase II Pembrolizumab A Randomized, Double-Blind Phase II Study of Adjuvant Pembrolizumab Versus Placebo in Head and Neck Cancers at High Risk for Recurrence- the PATHWay Study Active, not recruiting USA 0
NCT02953782 Phase Ib/II Cetuximab + Hu5F9-G4 Trial of Hu5F9-G4 in Combination With Cetuximab in Patients With Solid Tumors and Advanced Colorectal Cancer Completed USA 0
NCT02977156 Phase I Ipilimumab + JX-594 Immunization Strategy With Intra-tumoral Injections of Pexa-Vec With Ipilimumab in Metastatic / Advanced Solid Tumors. (ISI-JX) Completed FRA 0
NCT03109873 Phase I Metformin Metformin Hydrochloride in Affecting Cytokines and Exosomes in Patients With Head and Neck Cancer Completed USA 0
NCT03207867 Phase II Spartalizumab + Taminadenant A Phase 2 Study of NIR178 in Combination With PDR001 in Patients With Solid Tumors and Non-Hodgkin Lymphoma Terminated USA | ITA | FRA | ESP | DEU | BEL | AUT | AUS 7
NCT03264664 Phase I E7386 Study of E7386 in Participants With Selected Advanced Neoplasms Recruiting USA | GBR 0
NCT03329950 Phase I CDX-1140 + CDX-301 CDX-1140 A Study of CDX-1140 as Monotherapy or in Combination in Patients With Advanced Solid Tumors Completed USA 0
NCT03355560 Phase II Nivolumab Adjuvant Nivolumab After Salvage Resection in Head and Neck Cancer Patients Previously Treated With Definitive Therapy Active, not recruiting USA 0
NCT03578432 Phase I Everolimus Everolimus in Restoring Salivary Gland Function in Participants With Locally Advanced Head and Neck Cancer Treated With Radiation Therapy Terminated USA 0
NCT03621982 Phase I Camidanlumab tesirine Study of ADCT-301 in Patients With Selected Advanced Solid Tumors Terminated USA | GBR | BEL 0
NCT03816345 Phase I Nivolumab Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer Recruiting USA | CAN 0
NCT03915678 Phase II Atezolizumab + BDB001 Atezolizumab Combined With BDB001 AnD Immunogenic Radiotherapy in Patients With Advanced Solid Tumors (AGADIR) Recruiting FRA 0
NCT04020185 Phase Ib/II IMSA101 + unspecified PD-L1 antibody IMSA101 + unspecified PD-1 antibody IMSA101 Safety and Efficacy Study of IMSA101 in Refractory Malignancies Completed USA 0
NCT04044859 Phase I ADP-A2M4 cells ADP-A2M4 cells + Pembrolizumab ADP-A2M4 cells + Nivolumab ADP-A2M4CD8 as Monotherapy or in Combination With Either Nivolumab or Pembrolizumab in HLA-A2+ Subjects With MAGE-A4 Positive Tumors (SURPASS) Recruiting USA | ESP | CAN | BEL 0
NCT04065555 Phase I Avelumab + Subasumstat Cetuximab Cetuximab + Subasumstat Subasumstat Avelumab Intratumoral Microdosing of TAK-981 in Head and Neck Cancer Completed USA 0
NCT04105543 Phase I CLR 131 CLR 131 Combined With Radiation for Head and Neck Cancer Active, not recruiting USA 0
NCT04169841 Phase II Durvalumab + Olaparib + Tremelimumab Study Evaluating the Efficacy of a Double Immunotherapy Combined With Olaparib in Patients With Solid Cancers and Carriers of Homologous Recombination Repair Genes After Olaparib Treatment (GUIDE2REPAIR) Active, not recruiting FRA 0
NCT04225117 Phase II Enfortumab vedotin-ejfv A Study to Evaluate Enfortumab Vedotin in Subjects With Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) Recruiting USA | CAN 1
NCT04259450 Phase Ib/II AFM24 Study to Assess AFM24 in Advanced Solid Cancers Active, not recruiting USA | GBR | ESP | DEU 1
NCT04301011 Phase Ib/II TBio-6517 Pembrolizumab + TBio-6517 Study of TBio-6517 Given Alone or in Combination With Pembrolizumab in Solid Tumors (RAPTOR) Terminated USA | CAN 1
NCT04430842 Phase I QBS10072S Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QBS10072S Completed AUS 0
NCT04491942 Phase I BAY1895344 + Cisplatin BAY1895344 + Cisplatin + Gemcitabine Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer Active, not recruiting USA | CAN 0
NCT04514484 Phase I Cabozantinib + Nivolumab Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV Active, not recruiting USA 0
NCT04561362 Phase Ib/II BT8009 BT8009 + Pembrolizumab Study BT8009-100 in Subjects With Nectin-4 Expressing Advanced Malignancies Recruiting USA | ITA | GBR | FRA | ESP | CAN 0
NCT04574583 Phase Ib/II Bintrafusp alfa + FPV-CV301 + MVA-BN-CV301 + SX-682 Phase I/II Trial Investigating the Safety, Tolerability, Pharmacokinetics, Immune and Clinical Activity of SX-682 in Combination With BinTrafusp Alfa (M7824 or TGF-beta "Trap"/PD-L1) With CV301 TRICOM in Advanced Solid Tumors (STAT) Active, not recruiting USA 0
NCT04624113 Phase Ib/II Pembrolizumab + Tazemetostat Tazemetostat and Pembrolizumab in Patients With Pembrolizumab- or Nivolumab-Resistant, Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma Terminated USA 0
NCT04682431 Phase I Pembrolizumab + PY159 PY159 A Phase 1a/1b FIH Study of PY159 and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors Active, not recruiting USA 0
NCT04779151 Phase II Dostarlimab-gxly + Niraparib Basket Trial Exploring the Efficacy and Safety of the Combination of Niraparib and Dostarlimab (NIRADO) Recruiting FRA 0
NCT04837677 Phase I PRT1419 A Study of PRT1419 in Patients With Advanced Solid Tumors Completed USA 0
NCT04878484 Phase I TCRT-ESO-A2 Evaluate TCRT-ESO-A2 Autologous T Cells Expressing TCR Specific for NY-ESO-1 in Subjects With Advanced Solid Tumors Withdrawn 0
NCT04902443 Phase I Nivolumab + Pomalidomide Pomalidomide and Nivolumab in People With Virus-Associated Malignancies With or Without HIV Recruiting USA 0
NCT05038150 Phase I SGN1 Study of SGN1 in Patients With Advanced Solid Tumor Recruiting USA 1
NCT05060432 Phase Ib/II EOS-448 + Pembrolizumab EOS-448 + EOS100850 Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors (TIG-006) Recruiting USA | ITA | GBR | FRA | ESP | BEL 0
NCT05076760 Phase I MEM-288 Study of MEM-288 Oncolytic Virus in Solid Tumors Including Non-Small Cell Lung Cancer (NSCLC) Recruiting USA 0
NCT05103345 Phase I SGN1 Study of SGN1 Administered Via Intratumoral Injection in Patients With Advanced Solid Tumor Recruiting 2
NCT05142592 Phase I IPG7236 IPG7236 in Patients With Advanced Solid Tumors Unknown status USA 0
NCT05144698 Phase II RAPA-201 RAPA-201 Therapy of Solid Tumors Recruiting USA 0
NCT05420948 Phase II Pembrolizumab Carboplatin + Paclitaxel + Pembrolizumab A Study of Pembrolizumab in Combination With Chemotherapy for Head and Neck Cancer Recruiting USA 0
NCT05500508 Phase Ib/II AMXT1501 + Eflornithine Oral AMXT 1501 Dicaprate in Combination With IV DFMO Recruiting USA | AUS 0
NCT05572684 Phase Ib/II NC410 + Pembrolizumab A Safety, Tolerability and Efficacy Study of NC410 Plus Pembrolizumab in Participants With Advanced Unresectable or Metastatic Solid Tumors Recruiting USA 0
NCT05704985 Phase I DK210 DK210 + Nivolumab Paclitaxel DK210 + Pembrolizumab Oxaliplatin Capecitabine Fluorouracil Carboplatin Evaluating Safety and Biomarkers Using DK210 (EGFR) for Locally Advanced or Metastatic EGFR+ Tumors Recruiting USA 0
NCT05800964 Phase I AMG 305 Study to Explore the Safety, Tolerability, and Pharmacokinetics of AMG 305 in Subjects With Advanced Solid Tumors. Recruiting USA | FRA | ESP | DEU | AUS 1
NCT05948865 Phase I CPO301 A Phase 1 Study of CPO301 in Adult Patients With Advanced or Metastatic Solid Tumors Recruiting USA | CAN 0
NCT05985083 Phase I IMM47 A Study Of IMM47 In Subjects With Advanced Solid Tumors Recruiting AUS 0
NCT06052852 Phase Ib/II BDC-3042 + Pembrolizumab BDC-3042 Study of BDC-3042 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Malignancies Recruiting USA 0
NCT06056323 Phase Ib/II HB0045 A Study of HB0045 Injection in Patients With Advanced Solid Tumors Recruiting USA 0
NCT06108479 Phase I DF6215 Study of DF6215 in Patients With Advanced Solid Tumors Recruiting USA 0